Rezolute (RZLT) Q4 2026 Financial Results Summary
QuoteReporter
Rezolute (RZLT) Q4 2026: Improved Losses, Cash Decrease — Cautiously Optimistic
Rezolute, Inc. (Nasdaq: RZLT) reported its financial results for the fourth quarter and full fiscal year ended June 30, 2026. The company experienced a net loss of $20.5 million for Q4 2026, which is an improvement compared to a net loss of $24.4 million in Q4 2025, representing a decrease of $3.9 million or approximately -16% year-over-year. However, the full fiscal year net loss increased to $77.6 million from $74.4 million in the previous year, indicating a rise of $3.2 million or +4.3% year-over-year.
This quarter's results reflect a mixed performance for shareholders. While the reduction in quarterly losses is a positive sign, the overall increase in annual losses raises concerns about the company's financial health. The decrease in research and development (R&D) expenses from $20.9 million in Q4 2025 to $14.9 million in Q4 2026, a reduction of $6 million or -28.7%, is encouraging and suggests improved cost management. However, the significant drop in cash and cash equivalents from $167.9 million as of June 30, 2025, to $107.8 million as of June 30, 2026, a decrease of $60.1 million or -35.8%, is alarming and could impact future operations.
Key Financial Metrics:
- Cash, cash equivalents, and investments in marketable securities: $107.8 million as of June 30, 2026, down from $167.9 million as of June 30, 2025.
- R&D expenses: $14.9 million for Q4 2026, down from $20.9 million in Q4 2025; full year R&D expenses were $53.8 million, compared to $61.5 million in fiscal year 2025.
- G&A expenses: $6.7 million for Q4 2026, up from $5.0 million in Q4 2025; full year G&A expenses were $29.2 million, compared to $18.4 million in fiscal year 2025.
- Net loss: $20.5 million for Q4 2026, compared to $24.4 million in Q4 2025; full year net loss was $77.6 million, compared to $74.4 million in fiscal year 2025.
- Basic and diluted net loss per share: $0.20 for Q4 2026, compared to $0.26 for Q4 2025; full year loss per share was $0.75, compared to $0.73 for fiscal year 2025.
Dividend and Share Buyback
There were no announcements regarding dividends or share buybacks in this earnings release, which may indicate a focus on conserving cash amid rising losses.
Forward-Looking Catalysts
Investors should closely monitor the upcoming topline results from the ongoing upLIFT study, expected before the end of 2026. This Phase 3 study is crucial for Rezolute's future, as it aims to treat tumor hyperinsulinism (HI) and could significantly impact the company's market position and financial outlook. Additionally, updates regarding the sunRIZE study for congenital HI and any potential FDA feedback will be critical for assessing the viability of Rezolute's pipeline and its ability to navigate regulatory challenges.
In conclusion, while the reduction in quarterly losses is a positive development, the overall increase in annual losses and significant cash depletion raises concerns for shareholders. The upcoming results from clinical trials will be pivotal in determining the company's future trajectory and financial stability.
Here are the extracted tables from the provided press release:
Condensed Consolidated Statements of Income (in thousands)
Note: The amounts in the following tables are in thousands.
| Three Months Ended June 30, 2026 | Year Ended June 30, 2025 | |||
|---|---|---|---|---|
| Research and development | $14,900 | $20,900 | $53,700 | $61,500 |
| General and administrative | $6,700 | $4,987 | $29,200 | $18,400 |
| Total operating expenses | $21,600 | $25,887 | $82,900 | $79,900 |
| Loss from operations | $(21,600) | $(25,887) | $(82,900) | $(79,900) |
| Non-operating income | $1,000 | $1,460 | $5,380 | $5,400 |
| Net loss | $(20,600) | $(24,427) | $(77,520) | $(74,500) |
| Basic and diluted net loss per share | $(0.20) | $(0.26) | $(0.75) | $(0.99) |
| Weighted-average shares used to compute net income per share, basic | 104,000 | 94,300 | 103,000 | 75,000 |
Condensed Consolidated Balance Sheets (in thousands)
| June 30, 2026 | June 30, 2025 | |
|---|---|---|
| Cash and cash equivalents | $10,615 | $94,107 |
| Investments in marketable debt securities | $97,186 | $73,751 |
| Working capital | $99,093 | $159,233 |
| Total assets | $112,849 | $175,490 |
| Accumulated deficit | $(481,442) | $(403,856) |
| Total stockholders’ equity | $100,687 | $162,127 |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
